Navigation Links
MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor
Date:9/10/2013

ry and pre-clinical development of PWT143 to date," said Julie Cherrington, Ph.D., President and Chief Executive Officer of Pathway Therapeutics. "We continue to believe strongly in its potential to be an important drug for patients, and we are pleased that it is going into the hands of a team with the resources and drug development expertise to maximize that potential."

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor being developed for advanced hematologic diseases, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Results from a pilot Phase II clinical trial of Pracinostat in combination with Vidaza (azacitidine) in patients with MDS presented at the American Society of Hematology Annual Meeting in December 2012 showed an overall response rate of 89% (eight out of nine). In June 2013, the Company initiated a randomized, placebo-controlled Phase II trial of Pracinostat in combination with Vidaza in patients with previously untreated MDS. An open-label Phase II trial of Pracinostat in combination with Vidaza in elderly patients with AML unsuitable for induction therapy is expected to initiate in the fall of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a first-in-human Phase I trial of ME-344 in patients with solid refractory tumors are anticipated in October 2013. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe a
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
2. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
3. UHC to Launch New Specialty Pharmacy Program for Better Continuity of Patient Care, Improved Access to Specialty Pharmaceuticals
4. Pharmaceutical Giants Back Researchers in Unique US Competition
5. Several Market Access Drivers Provide Attractive Opportunities for Multinational Companies in Saudi Arabias Pharmaceutical Market
6. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
7. Sunshine Act 2013 Updates: A Checklist for Pharmaceutical Companies to Meet CMS Reporting
8. PDL BioPharma Provides Third Quarter 2013 Revenue Guidance of $97 Million
9. Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
10. Altaire Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution sold under several brands
11. SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Astex Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... HAMPTON, N.J. , March 5, 2015 ... MNK ), a leading global specialty biopharmaceutical company, and ... that they have entered into a definitive agreement under ... from a Madison Dearborn -led investor group in ... Subject to customary closing conditions, the parties expect ...
(Date:3/5/2015)... Mar. 05, 2015 Research and Markets ... "Global Rising Stars Outlook 2015" report to ... diseases are being sought after with fresh vigor as ... field which is poised to bring a paradigm change ... decades is the Stem cell therapy/Regenerative Medicine space. ...
(Date:3/5/2015)... 5, 2015 According to a ... Product (Systems and Disposables), by Type (Invasive, Minimally Invasive, ... and Ambulatory Sites) - Analysis & Global Forecast to ... expected to reach $1,107.4 Million by 2019 from $887.8 ... a CAGR of 4.5% during the forecast period. ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9Global Pharma Rising Stars Outlook 2015 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 3Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 4
... DUBLIN, Calif., June 16 SuperGen Inc.,(Nasdaq: ... to the discovery, rapid,development and commercialization of ... announced at the 13th Congress of the,European ... its JAK2 kinase inhibitor, prevents tumor cell ...
... COGENT-1 Study of CGT-2168 Expands to Europe; Focus ... Gastrointestinal Side Effects of Antiplatelet Therapy, ... Pharmaceuticals,Inc. today announced that the first patient has ... 3 study of its novel combination medicine,CGT-2168. The ...
Cached Medicine Technology:SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation 2European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals 2
(Date:3/5/2015)... York (PRWEB) March 05, 2015 Testosterone ... who allegedly suffered heart attacks, strokes and other serious ... testosterone therapies continue to move forward in the federal ... District of Illinois. According to a Case Management Order ... procedures for the use of master pleadings in the ...
(Date:3/5/2015)... 2015 Central Nebraska Imaging (CNI) is ... the brand’s new logo and optimized website. ... modern approach to expert diagnostic imaging, centered on patient ... built to be a resource for Nebraska patients and ... forms, communication and referral functionality, video content and resources ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Rhode Island Medical ... year in a row to support the Providence College (PC) ... donation covered the purchase of the ‘Think Pink’ uniforms, which ... Big East Conference opponent DePaul University at Alumni Hall/Mullaney Gymnasium ... continue our support of the PC women’s basketball’s ‘Pink Out’ ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... this March with extra savings on their ... important of health and nutrition, HomeCEUConnection.com is ... using the promo code, NUTRITION2015 . ... Professionals , HomeCEUConnection.com provides high-quality continuing ...
(Date:3/5/2015)... Tempe, AZ (PRWEB) March 05, 2015 ... in various kinds of income to the Arizona economy ... , The report, Demonstrating the Economic Value of Maricopa ... on investment of the Maricopa district in fiscal year ... Economic Modeling Specialists International (EMSI), an organization that ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 2Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 3
... statement by,SEIU President Andy Stern:, "Paula Hall -- ... and all her savings when she got sick and ... "Samara Knight -- a nursing assistant from Cleveland, Ohio, ... and the,medication her son needs -- will vote today., ...
... Inc. (Nasdaq:,CYBX) today announced that the company will report ... of its fiscal year ending April,24, 2009 on Wednesday, ... will,conduct a conference call to discuss those results on ... Year 2009 Second Quarter Results Conference Call Instructions, ...
... year,s Gold Sponsor of the Harvard Business School Health Conference. ... Center, Harvard Medical School, November 6 - 8, 2008. , ... ... International, Inc. , the world,s leading manufacturer and distributor of automated ...
... PALO ALTO, Calif., Nov. 4 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... at three upcoming investor conferences., On Tuesday, November ... Saks,Jazz Pharmaceuticals, CEO, will provide a corporate presentation at ... York City., On Wednesday, November 12, 2008 at ...
... U.S. Product Will Be Sold by A Uniquely-Trained Sales ... ... ProStrakan Group plc,(LSE: PSK) today announced that SANCUSO(R) (Granisetron Transdermal System),is now ... United States. Sancuso was approved by,the U.S. Food and Drug Administration (F.D.A.) ...
... vaccination rates far below goals, study finds , , TUESDAY, ... with asthma and other high-risk illnesses are getting flu ... rates from 1992 to 2002 for 18,703 adolescents with ... , During the study period, vaccination rates improved, but ...
Cached Medicine News:Health News:Today We Must Be the Change We Need 2Health News:Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Second Quarter Financial Results 2Health News:Lifeclinic International Lead Sponsor at Harvard Business School Health Conference 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 3Health News:Too Many High-Risk Teens Not Getting Flu Shots 2
Angled 45 degree shafts with 10.5 mm tying and 1 mm of tip crisscross serrated. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.2 inches....
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Angled Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Medicine Products: